TEMCELL® HS Inj, page-10

Regarding EB, I am so delighted to be involved with a Company that can help alleviate the pain of so many sick children. Well done to all the scientists and staff at JCR and Mesoblast. Seriously guys, be very very proud of your achievements. As for those shorters who would like to destroy companies such as MSB ... you are a bunch of immoral pr*#ks ! Having watched my sister die of a terminal condition, I had tears of joy rolling down my face on reading this news. The pain those poor kids must suffer from this horrible condition and the hope this must give them from their depression.

I am normally a reasonably hard nosed businessman but I am starting to feel differently about this company ( and others like it). So long as the Directors can keep their noses out of the trough, in terms of excessive remuneration ( other than well earned performance options) they all deserve our total support. We are close to read outs on CHF and CLBP which have incredible implications for tens of millions of people !
I started doing a statistical review of MSBs interim futility analysis linked to standard hospitalisation rates of end stage heart patients in the control group ... I am very encouraged by what I have so far found. When you extrapolate hospitalisations/morbidity and standard mortality rates against the required number of “MACE” events... I start to get very excited about the prospects for the potential outcome of the phase 3 CHF trial. Until I get my assumptions verified, I will not say anymore. To be reaonably certain,I am right ..I need a better steer on the male/female mix and age profiles of the patients who have enrolled. These are very important variables owing to the age standardised incidence ratio of 1.67 and the morbidity outcomes of older people. This is why the LVAD results were so misleading. This independently funded trial , had enrolled an unusually high mix of younger,mainly female, bridge to transplant patients which totally skewed the hospitalisation rates away from what we should expect from a more balanced group of mainly ischemic CHF patients ( which i understand from hints in the latest conference calls have been enrolled in our Phase 3 trails)
Much of what we should expect is clearly evident in the phase 2 results for Revascor. The management has recently told us that improvements in proprietary manufacturing processes to ensure batch consistency of serum free production and chemistry have now been approved by the FDA for aGVHD. This is key for reasons I will address another time.
If I am right... and this company is able to agree sensible terms with one of the “many” prospective global partners it is currently stated to be in discussions with.......the upside is spectacular.

As a general note, please be careful investing too high a proportion of your wealth in any one share.... particularly biotech. I have lost huge amounts of money on “dead certs” before. Ironically it is not foreseeable events I get caught on. It’s those “black swans” ... events which completely shock you ,such as new government regulations, accounting fraud (whether real or concocted bear raids) or market meltdown, etc., GLAH .